氯化腺苷类似物在治疗期间诱导慢性淋巴细胞白血病细胞中的AMPK和自噬
8-氯-腺苷(8-Cl-Ado)正处于急性髓系白血病和慢性淋巴细胞白血病(CLL)的I期临床试验中。研究显示,8-Cl-Ado处理CLL细胞可激活AMPK信号并诱导自噬,且在一项8-Cl-Ado的I期试验中,CLL淋巴细胞也观察到类似现象。结论认为8-Cl-Ado在体外及临床试验体内均诱导CLL淋巴细胞自噬。
要点
- 8-Cl-Ado处理可降低CLL细胞ATP水平并激活AMPK信号。
- 临床前孵育显示8-Cl-Ado诱导CLL细胞自噬。
- I期试验中CLL淋巴细胞亦观察到AMPK激活和自噬诱导。
核心结论
- 8-Cl-Ado治疗在体外及临床试验体内均诱导CLL淋巴细胞自噬。
研究设计与样本
- 临床前CLL细胞孵育研究及8-Cl-Ado的I期临床试验中CLL淋巴细胞的观察。
主要发现
- 临床前孵育中,8-Cl-Ado处理CLL细胞可激活AMPK并诱导自噬。
- 在8-Cl-Ado的I期试验中,CLL淋巴细胞也观察到AMPK激活和自噬诱导的类似现象。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
8-chloro-adenosine (8-Cl-Ado) is currently in phase-I clinical trials for acute myeloid leukaemia and chronic lymphocytic leukaemia (CLL). Previously, we demonstrated that treatment with 8-Cl-Ado leads to diminished ATP levels. We hypothesized that AMP-activated protein kinase (AMPK) signalling would be initiated in these cells, leading to induction of autophagy. AMPK activation and induction of autophagy were demonstrated during preclinical incubations in CLL cells with the analogues. Importantly, we extended similar observations in CLL lymphocytes during an 8-Cl-Ado phase-I trial. In conclusion, 8-Cl-Ado treatment induces autophagy in CLL lymphocytes in vitro as well as in vivo during clinical trial.
引用
- Stellrecht CM, Chen LS, Ayres ML, et al. Chlorinated adenosine analogue induces AMPK and autophagy in chronic lymphocytic leukaemia cells during therapy. Br J Haematol. 2017. PMID: 28737232. doi:10.1111/bjh.14859
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。